DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3ctmpk/global_adhd_drugs) has announced the addition of the "Global ADHD Drugs Market 2014-2018" report to their offering.
The Global ADHD Drugs market to grow at a CAGR of 5.33% over the period 2013-2018
This report covers the present scenario and the growth prospects of the Global ADHD Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of ADHD, which include:
- Stimulants
- Non-stimulants
One key trend emerging in this market is an increase in awareness, which is helping to increase the number of treatment-seeking patients.
According to the report, the major driving factor in this market is the high unmet need for appropriate drugs in the market. The current treatment options cannot cure the disorder completely, and thus market demand is high for this indication. Therefore, drugs that can cause disease remission in patients are expected to drive the market significantly.
Further, the report states that the unknown etiology of the disease is a major factor that restricts the growth of the market. This makes it difficult for drug makers to identify a target that can be used to develop a medication to cure ADHD.
Key Vendors
- Eli Lilly
- Janssen
- Novartis
- Shire
Key Topics Covered:
- Executive Summary
- List of Abbreviations
- Scope of the Report
- Product Profiles
- Market Research Methodology
- Introduction
- Market Landscape
- Market Segmentation by Product Type
- Market Segmentation by Route of Administration
- Market Segmentation by Dosage Form
- Geographical Segmentation
- Key Leading Countries
- Rate of Incidence and Prevalence
- Buying Criteria
- Market Growth Drivers
- Drivers and their Impact
- Market Challenges
- Impact of Drivers and Challenges
- Market Trends
- Trends and their Impact
- Vendor Landscape
- Pipeline Portfolio
- Key Vendor Analysis
For more information visit http://www.researchandmarkets.com/research/3ctmpk/global_adhd_drugs
